Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
For additional information please call: 1-800-718-1021
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
angiographic evidence of coronary atherosclerosis
You may not be if
Women who are pregnant or lactating, or planning to become pregnant.
Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid.
Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
Clareo Health | A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
